BGNE241220C170000
- 5.32
- 0.000.00%
BeiGene Newsroom
BeiGene Gets FDA Orphan Designation in Waldenstrom Macroglobulinemia Treatment
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (BGNE) Gets a Buy From TD Cowen
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials
Express News | JPMorgan Chase & Co's Short Position in Shares of Beigene Decreases to 1.66% on Dec. 11 From 2.42% - HKEX
BEIGENE issued 1.3 million shares due to the exercise of stock options.
BEIGENE (06160) announced that 1.3 million shares will be issued due to a Director exercising stock options on December 14, 2024.
Selected announcements | Ping An Insurance's original premium income in the current year is nearly 800 billion yuan; GANFENGLITHIUM's Goulamina spodumene project phase one has officially gone into production.
In the first 11 months, New China Life Insurance accumulated original insurance premium income of 163.1663 billion yuan, a year-on-year increase of 2.2%; Ideal Autos granted a total of 3.94697 million restricted stock units.
BEIGENE (06160.HK) issued 1.3 million shares due to the exercise of stock options.
Gelonghui reported on December 16 that BEIGENE (06160.HK) announced the issuance of 1.3 million ordinary shares due to a Director exercising stock options on December 14, 2024.
Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio?
Sector Update: Health Care Stocks Steady Premarket Friday
Sector Update: Health Care
CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland
Express News | JPMorgan Chase & Co's Long Position in Shares of Beigene Increases to 10.94% on Dec 9 From 9.92% - HKEX
US MOVERS&SHAKERS Dec 09-Dec 13, 2024
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
CSPC PHARMA and BEIGENE have entered into an exclusive licensing agreement for SYH2039.
CSPC PHARMA (01093) announced that the group has entered into an exclusive licensing agreement with BeiGene Switzerland GmbH (BEIGENE) for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as for any Pharmaceuticals composed of or containing this compound for development, manufacturing, and commercialization on a Global scale. Under the agreement, and in accordance with its terms and conditions, the group agrees to grant BEIGENE exclusive rights for the Global development, manufacturing, and commercialization of that compound and product. The group will receive a total of 1.50.
CSPC Pharmaceutical Partners With BeiGene on Innovative Cancer Drug
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor